Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study
International Journal of Neuropsychopharmacology · 10.08.2026 · 29 (8)
DOI: 10.1093/ijnp/pyag034 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 23.06.2026. Verfasst von Jennie Garcia-Olivares und 13 weiteren Autor:innen. Beteiligte Einrichtung: Supernus Pharmaceuticals, Inc., Rockville, MD, United States. Hauptthemen laut MEDLINE: Brain, Receptor, Serotonin, 5-HT2C, Viloxazine, Benzylamines. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Supernus Pharmaceuticals, Inc..
Abstract (Originalsprache)
Objective
Efficacy of viloxazine ER (extended-release capsules; Qelbree®) for attention-deficit/hyperactivity disorder (ADHD) is attributed to its ability to increase extracellular norepinephrine and dopamine in the medial prefrontal cortex by inhibiting norepinephrine transporters (NET); however, studies also suggest potentially relevant activity at serotonin (5-HT) receptors. In this study, we evaluated the target engagement by viloxazine at 5-HT2 receptor subtypes, in species with close similarities with humans, and whether viloxazine engages 5-HT2 receptor subtypes within a clinically relevant plasma concentration range.
Methods
This study utilized positron emission tomography (PET) and was conducted to measure the relationship between viloxazine plasma concentration and the changes in binding of the agonist radioligand [11C]CIMBI-36 to 5-HT2C/5-HT2A receptors in the brain of Macaca fascicularis monkeys.
Results
Viloxazine administration reduced the binding of [11C]CIMBI-36 at 5-HT2C receptors at a concentration 10- to 20-fold lower than at 5-HT2A receptors (EC50: 4.1 vs 45.1 μM, respectively), consistent with receptor binding affinities previously measured in vitro (Ki: 0.66 vs 16.0 μM, respectively). Unbound viloxazine plasma concentrations during these PET scans were compared to human unbound concentrations at doses used to treat ADHD. Our data suggest that at clinically relevant plasma concentrations, viloxazine occupies 60%-72% of 5-HT2C receptors.
Conclusion
Our results demonstrate that at unbound viloxazine plasma concentrations comparable with those clinically relevant for the treatment of ADHD, viloxazine occupies a high proportion of 5-HT2C receptors. Occupancy of and potential functional activity at 5-HT2C receptors could therefore contribute to the therapeutic activity of viloxazine in addition to inhibition of NET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Supernus Pharmaceuticals, Inc., Rockville, MD, United States.
- Perceptive Discovery, London, United Kingdom.
- Karolinska Institutet, Stockholm, Sweden.
- University of South Carolina School of Medicine, Greenville, SC, United States.
- Duke University, Durham, NC, United States.
ORCID-Profile: Jennifer Koch
Förderung
- Supernus Pharmaceuticals, Inc.
Zitieren
APA
Garcia-Olivares, J., Yegla, B., Ridler, K., Rizzo, G., Fan, Z., Amenta, A. L., Moren, A. F., Halldin, C., Stepanov, V., Koch, J., Yu, C., Rubin, J., Maletic, V., & Rabiner, E. A. (2026). Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study. International Journal of Neuropsychopharmacology, 29(8). https://doi.org/10.1093/ijnp/pyag034
Vancouver
Garcia-Olivares J, Yegla B, Ridler K, Rizzo G, Fan Z, Amenta AL, et al. Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study. International Journal of Neuropsychopharmacology. 2026;29(8). doi:10.1093/ijnp/pyag034
BibTeX
@article{GarciaOlivares2026,
author = {Garcia-Olivares, Jennie and Yegla, Brittney and Ridler, Khanum and Rizzo, Gaia and Fan, Zhen and Amenta, Amy Llopis and Moren, Anton Forsberg and Halldin, Christer and Stepanov, Vladimir and Koch, Jennifer and Yu, Chungping and Rubin, Jonathan and Maletic, Vladimir and Rabiner, Eugenii A},
title = {Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study},
journal = {International Journal of Neuropsychopharmacology},
year = {2026},
volume = {29},
number = {8},
doi = {10.1093/ijnp/pyag034}
}
EUVIMED